Full Press Release Details
FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma.
HURA
FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma
Key Takeaway: FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma
Price reaction · baseline $2.81 (2025-06-06 close) · 1 other HURA headline(s) in the window, move may be shared
day 0 close
+2.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+457%
120-day peak, hindsight
Typical move
7%
average across 2 past catalysts
Cash runway
~0 mo
High dilution risk
Lead asset
dalazatide
Phase 1 · Plaque Psoriasis